Skip to navigation Skip to content

Hereditary transthyretin amyloidosis (HTA) Program in Pharmaceutical Benefits Scheme (PBS) 012-24070419

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised patisiran or vutrisiran for patients with hereditary transthyretin amyloidosis (HTA).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Hereditary transthyretin amyloidosis (HTA) quick reference

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB367 form

Written

Electronic

S100:

patisiran

vutrisiran

No

OPA

Must be treated by or in consultation with a:

  • consultant with experience in the management of amyloid disorders

    Yes

    Grandfather

    PB369 form

    Written

    Electronic

    S100:

    patisiran

    No

    OPA

    Not specified

    Yes

    Grandfather

    PB369 form

    Written

    Electronic

    S100:

    vutrisiran

    No

    OPA

    Must be treated by or in consultation with a:

    • consultant with experience in the management of amyloid disorders

      Yes

      Continuing

      PB368 form

      Written

      Electronic

      S100:

      patisiran

      No

      OPA

      Not specified

      Yes

      Continuing

      PB368 form

      Written

      Electronic

      S100:

      vutrisiran

      No

      OPA

      Must be treated by or in consultation with a:

      • consultant with experience in the management of amyloid disorders

        Yes